Perioperative Durvalumab Plus Neoadjuvant Chemo Improves pCR, EFS in Resectable NSCLC

Perioperative durvalumab plus neoadjuvant platinum-based chemotherapy demonstrated a statistically significant improvement in pathologic complete response and event-free survival vs placebo plus chemotherapy in patients with resectable non–small cell lung cancer.

Related Keywords

United States ,Houston ,Texas ,American ,Johnv Heymach , ,Eli Lilly Co ,Genentech ,Novartis ,Astrazeneca ,Bristol Myers Squibb ,Chugai Pharmaceuticals ,American Joint Committee On Cancer ,University Of Texas Md Anderson Cancer Center ,Serono ,Glaxosmithkline ,Neck Medical Oncology ,Cancer Center ,American Joint Committee ,Mirati Therapeutics ,Eli Lilly ,Jazz Pharmaceutics ,Curio Science ,Blueprint Medicine ,Durvalumab ,Taacr ,Aegean Trial ,Nct03800134 ,Lung Cancer ,Nsclc ,Non Small Cell Lung Cancer ,